The Kazia Therapeutics Ltd [ASX:KZA] share price is following an upward trend. While this small-cap biotech may not be trying to treat COVID, they are trying to treat an equally sinister disease: glioblastoma.
Just under two weeks ago, Kazia Therapeutics Ltd [ASX:KZA] was making headlines. The company had received ‘the nod’ from the US Food and Drug Administration (FDA) it sorely needed...
The share price of oncology-focused biotech firm, KAZIA Therapeutics Ltd [ASX:KZA], soared this morning on the receipt of FDA designation for its brain cancer treatment. At time of writing the KZA share price is up 26 cents or 46.43%, trading at 82 cents per share.
This cancer treatment company is up 62.5%, at time of writing. A massive return for such a tiny stock. Better still, this result could actually end up saving lives.